Newsroom

News

August 11, 2022

The latest

argenx Announces European Commission Approval of VYVGART™ (efgartigimod alfa-fcab) for the Treatment of Generalized Myasthenia Gravis

Breda, the Netherlands

argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the European Commission (EC) has granted marketing authorization for VYVGART™ (efgartigimod alfa-fcab) as an add-on to standard therapy for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive.

argenx Stories

See where we started — and where we’re going — as we chart a new course together in immunology.

Past Press Releases

July 28, 2022

argenx Reports Half Year 2022 Financial Results and Provides Second Quarter Business Update

July 21, 2022

argenx to Report Half Year 2022 Financial Results and Second Quarter Business Update on July 28, 2022

June 24, 2022

argenx Receives Positive CHMP Opinion for Efgartigimod for the Treatment of Adult Patients with Generalized Myasthenia Gravis in Europe

June 1, 2022

argenx to Present at Upcoming Investor Conferences

Download assets

Get photos, fact sheets, illustrations and more.

Join the team

Dare to do more with a thriving career at Argenx.

Find your career

Follow us

Get the latest news and info via our social media channels.